China NMPA Drug Inspection - Chongqing Kangle Pharmaceutical Co., Ltd - Eucommia

On March 24, 2017, the State Administration for Market Regulation issued an announcement detailing findings from inspections conducted by the Shaanxi Provincial Institute for Food and Drug Control. These inspections revealed 35 batches of substandard Traditional Chinese Medicine (TCM) decoction pieces, specifically Eucommia ulmoides, produced by 34 enterprises, including Shaanxi Shangluo Panlong Botanical Pharmaceutical Co., Ltd. and multiple other manufacturers such as Anguo Qi'an Pharmaceutical Co., Ltd. The primary issue identified was that these products failed to meet established quality standards.

In response to these findings, the relevant provincial food and drug administrations immediately implemented control measures. These included the sealing and seizure of the non-compliant products, mandating the suspension of sales and usage, initiating product recalls, and requiring the involved companies to undertake rectification. The State Food and Drug Administration (SFDA) further directed local authorities to investigate these illegal activities, citing Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*. The SFDA required public disclosure of the handling results for the implicated enterprises within three months and established a procedure for manufacturers to contest product authenticity, which would trigger additional investigations and potential severe penalties if non-compliance is confirmed. These actions underscore a commitment to maintaining the quality and safety of medicinal products within the market.